Skip to main content

Marta Rebull Santamaria

Institutions of which they are part

Research technician
Biomedical Research in Gynaecology
Vall Hebron Institut de Recerca

Marta Rebull Santamaria

Institutions of which they are part

Research technician
Biomedical Research in Gynaecology
Vall Hebron Institut de Recerca

Projects

Estudio preclínico de la combinación de terapias anti-HER2 e inhibidores de PARP en el cáncer de endometrio HER2 positivo con Deficiencia de Recombinación Homóloga (HRD).

IP: Valeria Tubita
Collaborators: Francesc Xavier Serra Marin, Eva Colas Ortega, Antonio Gil Moreno, Marta Rebull Santamaria, Lourdes Elena Salazar Huayna
Funding agency: Asociación Española Contra el Cáncer
Funding: 8539.84
Reference: SNRGS259715TUBI
Duration: 01/12/2025 - 30/11/2027

Búsqueda de firmas proteómicas y dianas terapéuticas en el cáncer de ovario seroso de alto grado avanzado resistente a platino

IP: Antonio Gil Moreno
Collaborators: Vicente Bebia Conesa, Francesc Xavier Serra Marin, Marta Rebull Santamaria, Martina Angeles Fite, Melissa Bradbury Lobato, Lourdes Elena Salazar Huayna, Beatriz Villafranca Magdalena, Melek Denizli , Valeria Tubita
Funding agency: Instituto de Salud Carlos III
Funding: 196250
Reference: PI24/01509
Duration: 01/01/2025 - 31/12/2027

ScreenEC, validació d'una eina de triatge no invasiu en càncer d'endometri

IP: Eva Colas Ortega
Collaborators: Vicente Bebia Conesa, Francesc Xavier Serra Marin, Josep Castellví Vives, Silvia Cabrera Diaz, Antonio Gil Moreno, Marta Rebull Santamaria, Ana Luzarraga Aznar, Irene De la Calle Fuentes, Lourdes Elena Salazar Huayna
Funding agency: Generalitat de Catalunya - Departament de Salut
Funding: 99946
Reference: SLT036/24/000059
Duration: 21/12/2024 - 31/12/2026

Desarrollo de CEMARK-Px, un método in vitro para el diagnóstico objetivo y preciso del tipo y grado histológico del cáncer de endometrio en fluido uterino

IP: Eva Colas Ortega
Collaborators: Vicente Bebia Conesa, Silvia Cabrera Diaz, Antonio Gil Moreno, Marta Rebull Santamaria, Ana Luzarraga Aznar, Irene De la Calle Fuentes, Lourdes Elena Salazar Huayna, Melek Denizli
Funding agency: Instituto de Salud Carlos III
Funding: 278300
Reference: DTS23/00091
Duration: 01/01/2024 - 31/12/2026

Related news

The ten groups within the Cancer Area combine basic, translational and clinical research to identify new targets, biomarkers and therapeutic strategies

The study evaluated the results of combining SYD985, a HER2 antibody conjugated to a potent cytotoxic drug, and niraparib, an inhibitor of DNA damage repair.

Researchers from the centre took part in international debates on AI in healthcare, spin-offs emerging from research were presented, and several initiatives linked to VHIR received recognition in the field of entrepreneurship.

Related professionals

Nataly Reyes Calderon

Nataly Reyes Calderon

Predoctoral researcher
General Surgery
Read more
Susana Núñez Pereira

Susana Núñez Pereira

Main researcher
Spine Research Unit
Read more
Coro Bescós Atin

Coro Bescós Atin

Head of group
New Technologies and Craniofacial Microsurgery
Read more
Fernando Clau Terre

Fernando Clau Terre

Senior researcher
Shock, Organ Dysfunction and Resuscitation
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.